Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Tarih
2020
Yazar
Villegas, A.
Paz-Ares, L.
Spira, A.
Raben, D.
Planchard, D.
Cho, B. C.
ÖZGÜROĞLU, Mustafa
Daniel, D.
Vicente, D.
Hui, R.
Murakami, S.
Spigel, D.
Senan, S.
Langer, C. J.
Perez, B. A.
Boothman, A-M
Broadhurst, H.
Wadsworth, C.
Dennis, P. A.
Antonia, S. J.
Faivre-Finn, C.
Üst veri
Tüm öğe kaydını göster
Özet
Background: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression.
Bağlantı
http://hdl.handle.net/20.500.12627/161034
https://doi.org/10.1016/j.annonc.2020.03.287
Koleksiyonlar